相关实验视频

Updated: Feb 19, 2026

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

YY1化参与DbCM心肌细胞脂毒性,通过抑制ANXA3诱导的微脂性

Jiayin Chai¹, Lijie Han², Degang Mo³

¹Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China; Department of Pathology, Capital Center for Children's Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, China.

|February 17, 2026

概括

糖尿病心肌病症涉及心脏细胞中的脂质积累,这是由于减少了素A3 (ANXA3) 的原因. 在2型糖尿病 (T2DM) 中YY1蛋白的化会损害ANXA3,恶化脂质沉积和心脏损伤.

科学领域:

心血管生物学心血管生物学
代谢疾病代谢疾病
分子机制的分子机制

背景情况:

在2型糖尿病 (T2DM) 中的糖尿病心肌病 (DbCM) 标志着心脏细胞中有害的脂质积累.
素A3 (ANXA3),一种抑制脂质储存的蛋白质,在T2DM中表达较少,但其在DbCM中的作用尚不清楚.
在T2DM中,化应激会导致蛋白质化异常,可能会影响ANXA3的表达,并导致心脏功能障碍.

研究的目的:

研究ANXA3在T2DM诱导的心肌脂沉积中的作用.
探索蛋白质化,特别是YY1的化如何影响ANXA3的表达,并有助于DbCM.
确定治疗点,以减轻糖尿病心肌病中的脂质积累.

主要方法:

建立了一个T2DM小鼠模型 (db/db小鼠) 来研究DbCM.
利用心脏特异性腺相关病毒过度表达ANXA3并评估其对脂质沉积的影响.
服用过氧酸盐清除剂,观察对脂质滴积累的影响.
采用现场定向突变发生法来识别YY1.1上的酸铁残留物.

主要成果:

在DbCM中,ANXA3表达是下调的,它通过微脂质-Rab7a通路调节脂质滴降解.
YY1积极调节ANXA3基因转录.
在T2DM条件下,在Y185位点的YY1化会降低其转录ANXA3基因的能力.

结论:

在Y185和Y383中,T2DM诱导YY1化,抑制YY1核转位和降低ANXA3转录.
通过抑制Rab7a,ANXA3的下调会损害微脂质,导致脂质沉积并加剧DbCM.
向YY1化或增强ANXA3介导的微脂质提供了DbCM的潜在治疗策略.

关键词:

附录A3 是一个附录.脂肪毒性脂肪毒性微脂质菌是一种微脂质菌.亚酸盐的化物这就是T2DM.

更多相关视频

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

Visualization of Cell Cycle Variations and Determination of Nucleation in Postnatal Cardiomyocytes

Visualization of Cell Cycle Variations and Determination of Nucleation in Postnatal Cardiomyocytes

Published on: February 24, 2017

相关概念视频

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...